Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?

doi:10.5497/wjp.v3.i4.72

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12882)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

977

WORD

354

HTML

8675

Figures (1-4)

461

Tables (1-1)

155

Sum=10622

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1102

Download

1158

Sum=2260

Dec 9, 2014 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Pharmacol. Dec 9, 2014; 3(4): 72-85
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.72

Table 1 Nanoparticles for breast cancer therapy

Nanoparticle	Delivered active molecule	Activity on HER2+breast cancer cells or tumors
TZ-polymeric NPs[90]	DOX	nuclear drug delivery and apoptotic effect (in vitro study)
TZ-PLGA-PEG NPs[91]	DTX	HER2 specific targeting, cellular internalization and cytotoxic activity (in vitro study)
anti-HER2 affibody-PLA-PEG-Mal NPs[70]	Pxtl	HER2 specific targeting, cellular internalization and cytotoxic activity (in vitro study)
rhuMAbHER2 (Fab’)-PLGA NPs[92]	PE38KDEL	HER2 specific targeting, cellular internalization and cytotoxic activity (in vitro study); anti-tumor activity (in vivo study)
scFv-PEG-PLA NPs[96]	siPlk1	cellular internalization, Plk1 silencing, apoptotic effect (in vitro study); siPlk1 accumulation in tumors and anti-tumor activity (in vivo study)
Herceptin-PLA-TPGS+TPGS-COOH NPs[97]	DTX/IOs	cellular internalization and cytotoxic activity (in vitro study)
anti HER2-PEG–gold NPs[98]	phthalocyanine	HER2 specific cytotoxic activity (in vitro study)

TZ: Trastuzumab; DOX: Doxorubicin; DTX: Docetaxel; PLGA: Poly-D,L-lactic-co-glycolic acid; PEG: Poly ethylene glycol; IOs: Iron oxides; HER2: Human epidermal growth factor receptor 2.

Citation: Mazzucchelli S, Truffi M, Fiandra L, Sorrentino L, Corsi F. Targeted approaches for HER2 breast cancer therapy: News from nanomedicine? World J Pharmacol 2014; 3(4): 72-85
URL: https://www.wjgnet.com/2220-3192/full/v3/i4/72.htm
DOI: https://dx.doi.org/10.5497/wjp.v3.i4.72